NASDAQ:PRTK
Delisted
Paratek Pharmaceuticals Stock News
$2.23
+0 (+0%)
At Close: Dec 19, 2023
Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board
12:30pm, Tuesday, 20'th Dec 2022 GlobeNewswire Inc.
BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company’s independent directors of the Board have appointed Jeffrey Stein, PhD as its
BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness i
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
10:45pm, Thursday, 01'st Dec 2022 GlobeNewswire Inc.
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sa
Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
04:05pm, Monday, 21'st Nov 2022
BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
08:07am, Monday, 07'th Nov 2022 Benzinga
Gainers
Peak Bio, Inc. (NASDAQ: PKBO) shares surged 105.8% to close at $7.82 on Friday. Peak Bio reported closing of up to $100 million common stock purchase transaction with White Lion Capital. Lade
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
04:54pm, Friday, 04'th Nov 2022 Benzinga
Gainers
Peak Bio, Inc. (NASDAQ: PKBO) jumped 115% to $8.17. Peak Bio reported closing of up to $100 million common stock purchase transaction with White Lion Capital. Ladenburg Thalmann initiated cov
Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million
08:05pm, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates
06:48pm, Thursday, 03'rd Nov 2022
Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05pm, Tuesday, 01'st Nov 2022 GlobeNewswire Inc.
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sa
Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference
08:00am, Tuesday, 01'st Nov 2022
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract
12:00pm, Monday, 31'st Oct 2022 GlobeNewswire Inc.
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone fo
Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3
08:00am, Tuesday, 25'th Oct 2022
BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022
08:05pm, Thursday, 13'th Oct 2022 GlobeNewswire Inc.
Highlights include data from non-clinical and microbiology programs and real-world patient use
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05pm, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
BOSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sa
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05pm, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-s
